"Pfizer" stops developing the drug "Dangerbrone" to lose weight

‘Pfizer’ said on Monday that it stopped developing the experimental medicine ‘Dangerbrones’ for weight loss, which is taken by mouth, after a patient with an experiment was sustained to a liver injury that is likely to be caused by the pills, and disappeared after he stopped eating it. The company tested the property in multiple doses, so it was taken once a day, after the development of a copy with specifications was canceled to use twice a day twice a day in the late 2023, because most patients withdrew in the middle of the experiment due to repeated seizures of nausea, vomiting and other side effects. The drug “Dangerbrone” of “Pfizer” was a suitable alternative to the profitable weight loss drug market, which is currently dominated by the “wigofi drug” for “Novo Nordesk” and “Zipond” for “Eli Lily”, which is taken once a week through the injection path. This category has attracted great attention to drug businesses and investors, and its sales are expected to amount to $ 150 billion in the coming years. A few businesses work on the development of weight loss medicines taken by the mouth, driven by the tremendous popularity of the injection medicine, which targets a intestinal hormone called “GB-1”. The company is expected to announce “Eli Lili” soon the results of the third phase of experiments on Ovurcelbron tablets. “Pfizer stops developing the property gives the business to the starting point, because the other medicine is all obese in the early stages of clinical trials.”